Senti Biosciences Inc (SNTI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$0.29-7.95%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Senti Biosciences is pioneering programmable cell therapies with a strong pipeline. Management aims to improve financial performance despite a net loss of $4.22M in Q1 2026. The company’s market cap is about $33.6M, and recent M&A activity shows strategic moves. If they can stabilize losses and execute capital allocation, growth is possible.
Senti Biosciences remains loss-making with EPS estimates of -$1.16 for 2026 and -$0.95 for 2027. Revenue is minimal, with $0.01M reported and $33,330 estimated for 2026. Capital allocation risks and ongoing losses threaten financial stability and growth prospects.
The market prices Senti Biosciences near $0.11 per share, reflecting high uncertainty and loss-making status. Our fair value aligns with this, implying the market expects continued losses and limited near-term revenue growth. Our view differs by focusing on potential turnaround if financials improve.
Breaks if: incurs new debt or obligations beyond current levels
Breaks if: net loss exceeds $4.22M in FY26
revenue falls below $10M in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as SNTI is navigating a volatile management landscape while pursuing pivotal clinical trials. The current thesis state is intact, despite recent challenges and mixed financial performance.
The market appears to reflect a premium valuation compared to peers, suggesting that some fragility is already priced in. However, the overall expectations may not fully account for the company's recent struggles and high-risk profile.
Fundamentals may remain mixed in the near term, as management is focused on advancing clinical development and engaging in strategic transactions. However, the increase in net loss indicates challenges in reducing cash burn, which could affect future performance.
The thesis hinges on several factors, including the performance of sector bellwethers and the company's ability to execute on its clinical and strategic priorities. Additionally, macroeconomic conditions, such as job reports, could impact sentiment in the healthcare sector.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, SNTI's trajectory will depend on its management execution and external market conditions. Not investment advice.